Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-reported Outcomes With Bifeprunox or Olanzapine in Schizophrenia
NCT00230828Phase 3Completed
- Sponsor
- Solvay
- Start
- May 2005
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia (2 arms), sponsored by Solvay. Primary endpoint: Patient-reported health economic outcomes. Started May 2005; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00230828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230828.